Major Alzheimer’s trial disappoints, yet researchers see reason for hope

Novo Nordisk halted its trial early after semaglutide failed to slow cognitive decline.

 

GLP-1 drugs didn't slow Alzheimer's, but the failure taught researchers something valuable Novo Nordisk recruited 3,808 people with early Alzheimer's and tested whether semaglutide — the drug in Ozempic and Wegovy — could slow their cognitive decline. After three years, the answer was unequivocal: it couldn't. The company announced in a press release that they had halted the Evoke trials early and cancelled a planned extension. The rationale seemed sound. People with obesity face a higher risk of developing Alzheimer's. Type 2 diabetes increases that risk further. Some scientists call Alzheimer's "type 3 diabetes" because of the role of insulin resistance in the brain. GLP-1 drugs successfully treat both obesity and diabetes, so why not Alzheimer's too? "These trial results are another reminder that Alzheimer's is driven by several different biological processes," explained Susan Kohlhaas, Executive Director of Research and Partnerships at Alzheimer's Research UK. "No single approach is likely to be enough." Semaglutide did reduce Alzheimer's biomarkers significantly, just not enough to stop cognitive decline. Experts point to a critical limitation: GLP-1 drugs have very limited ability to cross the blood-brain barrier and reach the central nervous system, where insulin resistance does its damage. Yet researchers aren't ready to abandon this approach entirely. "I wouldn't interpret this result as evidence that GLP-1 agonists are ineffective for Alzheimer's disease more broadly," said Matt Kaeberlein, professor of pathology at UW Medicine. He sees potential in combining GLP-1 drugs with lifestyle changes as prevention before symptoms emerge. To learn why these drugs might work better as prevention before symptoms appear, and what researchers will test next, jump to "Can GLP-1s actually help treat Alzheimer's? Latest trial data." Also making headlines this week: 🧠 Staying active in middle age and beyond cuts dementia risk 💊 Experimental cholesterol pill slashes 'bad cholesterol' by nearly 60% 🩺 Blood pressure medication shows promise against aggressive brain tumors We love to hear from you, so please email us if you have any feedback, comments, or questions about this weekend's Sunday Supplement. Stay informed and stay healthy! Tim Snaith Newsletter Editor, Medical News Today

MNT RESOURCE What can cause high triglycerides and low HDL? The combination of high triglycerides and low high-density lipoprotein (HDL) cholesterol can arise from unhealthy lifestyle choices. Learn how to treat it. The combination of high triglycerides and low high-density lipoprotein (HDL) cholesterol can arise from unhealthy lifestyle choices. Learn how to treat it. READ ON

In case you missed it Common blood pressure drug may help slow aggressive brain cancer   Hydralazine, a drug commonly used to treat high blood pressure and preeclampsia, may also help stop the growth of glioblastoma, an aggressive brain tumor, new research suggests. Read on   New pill reduces 'bad' cholesterol levels by almost 60%   An experimental drug called enlicitide reduced levels of low-density lipoprotein (LDL), or "bad" cholesterol by almost 60% in a clinical trial, offering hope as an alternative to statins. Read on   Physical activity at 2 life stages may help lower dementia risk   People who stay physically active throughout middle age as well as later in life could lower their risk of dementia, a new paper based on Framingham heart study data shows. Read on   Regular bedtimes could help lower blood pressure, study shows   Going to the bed at the same time every night could help regulate blood pressure, a small proof-of-concept study suggests. Read on   Keto diet may help with depression but jury is out on anxiety   A ketogenic diet may help improve depression symptoms but the evidence regarding its potential effect on anxiety remains inconclusive, a review has concluded. Read on   MORE HEALTH NEWS

Follow Us You are receiving this newsletter because you subscribed on our web site, Medical News Today. Did a friend send you this email? Subscribe here. View in Browser | Privacy Policy | Unsubscribe Our website services, content, and products are for informational purposes only. Medical News Today does not provide medical advice, diagnosis, or treatment and should not be used as a substitute for medical advice from a healthcare professional. Medical News Today encourages you to make any treatment decisions with your healthcare professional. Medical News Today is owned by RVO Health. © 2025 RVO Health 1101 Red Ventures Drive Fort Mill, SC 29707